UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathology of malignant liver tumors

Author
Arief Suriawinata, MD
Section Editors
Richard M Goldberg, MD
Kenneth K Tanabe, MD
Deputy Editor
Diane MF Savarese, MD

INTRODUCTION

Primary malignant liver tumors resemble and arise from the major constituent cells of the liver, namely hepatocytes (giving rise to hepatocellular carcinoma, [HCC]), biliary epithelial cells (cholangiocarcinoma [CC] and biliary cystadenocarcinoma), endothelial cells (angiosarcoma, epithelioid hemangioendothelioma), or combinations of these cells with various mesenchymal cells (eg, hepatoblastoma) [1]. Some (eg, combined hepatocellular-cholangiocellular carcinoma) represent collision of two different tumors or may result from malignant transformation of hepatic progenitor cells with differentiation along two different cell lineages. Secondary liver tumors (ie, metastases from a non-liver primary site) are the most frequent malignant liver tumor, outnumbering primary malignant liver tumors by a large margin (30 to 1 in one series [1]) particularly in patients without underlying liver disease.

Several premalignant lesions that arise in the liver have been extensively studied in order to better understand both hepatocarcinogenesis and cholangiocarcinogenesis [2,3].

Premalignant hepatocellular lesions include:

Dysplastic foci, characterized by cytological small cell change

Dysplastic nodules, encompassing low-grade dysplastic nodule and high-grade dysplastic nodule

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue May 24 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Goodman ZD. Neoplasms of the liver. Mod Pathol 2007; 20 Suppl 1:S49.
  2. Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Surg Oncol Clin N Am 2009; 18:215.
  3. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131:1758.
  4. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105:65.
  5. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: classification of tumours of the digestive system, 4th, Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds), IARC, Lyon 2010. p.205.
  6. Eggel H. Uber das primare Carcinom der Leber. Beitr z path Anat z allg Path 1910; 3:5060.
  7. Okuda K, Peters RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984; 54:2165.
  8. Nakashima T, Kojiro M. Hepatocellular carcinoma. In: An atlas of its pathology, Springer-Verlag, Tokyo 1987.
  9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693.
  10. Plessier A, Codes L, Consigny Y, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10:S86.
  11. D'Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15:1278.
  12. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080.
  13. Lauwers GY, Vauthey JN. Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. Hepatogastroenterology 1998; 45 Suppl 3:1197.
  14. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983.
  15. Le Bail B, Bernard PH, Carles J, et al. Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J Hepatol 1997; 27:835.
  16. Theise ND, Curado MP, Franceschi S, et al.. Hepatocellular carcinoma. In: Classification of tumours of the Digestive System, 4th, Bosman FT, Carneiro F, Hruban RH, Theise ND. (Eds), IARC, Lyon 2010. p.213.
  17. Deugnier YM, Charalambous P, Le Quilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18:1363.
  18. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997; 26:1415.
  19. Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001; 39:66.
  20. Koo JS, Kim H, Park BK, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 2008; 42:738.
  21. Nam SW, Park JY, Ramasamy A, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005; 42:809.
  22. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25:133.
  23. Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007; 17:2969.
  24. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006; 50:257.
  25. Lin F, Abdallah H, Meschter S. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver. Diagn Cytopathol 2004; 30:92.
  26. Lei JY, Bourne PA, diSant'Agnese PA, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol 2006; 125:519.
  27. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16.
  28. Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88:78.
  29. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30:17.
  30. Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004; 30:1.
  31. Nguyen T, Phillips D, Jain D, et al. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Arch Pathol Lab Med 2015; 139:1028.
  32. Yoneda N, Sato Y, Kitao A, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest 2011; 91:262.
  33. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94:851.
  34. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49:138.
  35. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45:725.
  36. Park YN, Kojiro M, Di Tommaso L, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007; 109:915.
  37. Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011; 31:61.
  38. Li W, Tan D, Zenali MJ, Brown RE. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 2009; 3:238.
  39. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343:1010.
  40. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004; 39:798.
  41. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980; 46:372.
  42. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013; 6:3.
  43. Ward SC, Huang J, Tickoo SK, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010; 23:1180.
  44. Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol 2011; 24:390.
  45. Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol 2015; 28:822.
  46. Sempoux C, Jibara G, Ward SC, et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis 2011; 31:49.
  47. Chan ES, Yeh MM. The use of immunohistochemistry in liver tumors. Clin Liver Dis 2010; 14:687.
  48. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 2012; 7:149.
  49. Al-Muhannadi N, Ansari N, Brahmi U, Satir AA. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material. Ann Hepatol 2011; 10:508.
  50. Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012; 55:1876.
  51. Matsuda M, Hara M, Suzuki T, et al. Synchronously resected double primary hepatic cancers - hepatocellular carcinoma and cholangiolocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13:571.
  52. Shiota K, Taguchi J, Nakashima O, et al. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep 2001; 8:263.
  53. Sempoux C, Fan C, Singh P, et al. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 2011; 31:104.
  54. Kanamoto M, Yoshizumi T, Ikegami T, et al. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver:a case report. J Med Invest 2008; 55:161.
  55. Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: WHO Classification of Tumours of the Digestive System, 4th, BosmanFT, Carneiro F, Hruban RH, Theise ND. (Eds), IARC, Lyons 2010. p.225.
  56. Theise ND, Yao JL, Harada K, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003; 43:263.
  57. Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010; 2:419.
  58. Theise ND, Nakashima O, Park YN, Nakanuma Y.. Combined hepatocellular-cholangiocarcinoma. In: WHO Classification of Tumours of the Digestive System, 4th, Bosman FT, Carneiro F, Hruban RH, Theise ND.. (Eds), IARC, Lyon 2010. p.225.
  59. Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37:496.
  60. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20:701.
  61. Zen Y, Sasaki M, Fujii T, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 2006; 44:350.
  62. Sato Y, Harada K, Sasaki M, Nakanuma Y. Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma. Virchows Arch 2013; 462:421.
  63. Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int 2010; 60:419.
  64. Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44:1333.
  65. Nakanishi Y, Zen Y, Hirano S, et al. Intraductal oncocytic papillary neoplasm of the bile duct: the first case of peribiliary gland origin. J Hepatobiliary Pancreat Surg 2009; 16:869.
  66. Nanashima A, Kinoshita N, Nakanuma Y, et al. Clinicopathological features of "intraductal papillary neoplasm of the bile duct" and patient outcome after surgical resection. Hepatogastroenterology 2008; 55:1167.
  67. Nakanuma Y, Curado MP, Franceschi S, et al. Intrahepatic cholangiocarcinoma. In: WHO classification of tumours of the digestive system, 4th, Bosman FT, Carneiro F, Hruban R, Theise N (Eds), IARC, Lyon 2010. p.217.
  68. Tsui WMS, Adsay NV, Crawford JM, et al. Mucinous cystic neoplasms of the liver. In: WHO Classification of Tumours of the Digestive System, 4th, Bosman A, Carneiro F, Hruban R, Theise N (Eds), IARC, Lyon 2010. p.236.
  69. Buetow PC, Buck JL, Pantongrag-Brown L, et al. Biliary cystadenoma and cystadenocarcinoma: clinical-imaging-pathologic correlations with emphasis on the importance of ovarian stroma. Radiology 1995; 196:805.
  70. Abdul-Al HM, Makhlouf HR, Goodman ZD. Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. Virchows Arch 2007; 450:691.
  71. Zimmerman A, Saxena R. Hepatoblastoma. In: WHO Classification of Tumours of the Digestive System, 4th, Bosman FT, Carneiro F, Hruban RH, Theise ND. (Eds), IARC, Lyon 2010. p.229.
  72. Gonzalez-Crussi F. Undifferentiated small cell ("anaplastic") hepatoblastoma. Pediatr Pathol 1991; 11:155.
  73. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74:593.
  74. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53:1016.
  75. Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26:19.
  76. Weiss SW, Ishak KG, Dail DH, et al. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 1986; 3:259.
  77. Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999; 85:562.
  78. Walsh MM, Hytiroglou P, Thung SN, et al. Epithelioid hemangioendothelioma of the liver mimicking Budd-Chiari syndrome. Arch Pathol Lab Med 1998; 122:846.
  79. den Bakker MA, den Bakker AJ, Beenen R, et al. Subtotal liver calcification due to epithelioid hemangioendothelioma. Pathol Res Pract 1998; 194:189.
  80. Groeschl RT, Miura JT, Oshima K, et al. Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol 2014; 109:483.
  81. Ishak KG, Sesterhenn IA, Goodman ZD, et al. Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol 1984; 15:839.
  82. Antonescu C. Malignant vascular tumors--an update. Mod Pathol 2014; 27 Suppl 1:S30.
  83. Ferrell L. Malignant liver tumors that mimic benign lesions: analysis of five distinct lesions. Semin Diagn Pathol 1995; 12:64.
  84. Suriawinata AA, Thung SN. Malignant liver tumors. Clin Liver Dis 2002; 6:527.
  85. Bioulac-Sage P, Laumonier H, Laurent C, et al. Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis 2008; 28:302.
  86. Sherman M. Vinyl chloride and the liver. J Hepatol 2009; 51:1074.
Topic Outline

GRAPHICS